Literature DB >> 10438828

Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.

N W Blake1, A Moghaddam, P Rao, A Kaur, R Glickman, Y G Cho, A Marchini, T Haigh, R P Johnson, A B Rickinson, F Wang.   

Abstract

Most humans and Old World nonhuman primates are infected for life with Epstein-Barr virus (EBV) or closely related gammaherpesviruses in the same lymphocryptovirus (LCV) subgroup. Several potential strategies for immune evasion and persistence have been proposed based on studies of EBV infection in humans, but it has been difficult to test their actual contribution experimentally. Interest has focused on the EBV nuclear antigen 1 (EBNA1) because of its essential role in the maintenance and replication of the episomal viral genome in latently infected cells and because EBNA1 endogenously expressed in these cells is protected from presentation to the major histocompatibility complex class-I restricted cytotoxic T-lymphocyte (CTL) response through the action of an internal glycine-alanine repeat (GAR). Given the high degree of biologic conservation among LCVs which infect humans and Old World primates, we hypothesized that strategies essential for viral persistence would be well conserved among viruses of this subgroup. We show that the rhesus LCV EBNA1 shares sequence homology with the EBV and baboon LCV EBNA1 and that the rhesus LCV EBNA1 is a functional homologue for EBV EBNA1-dependent plasmid maintenance and replication. Interestingly, all three LCVs possess a GAR domain, but the baboon and rhesus LCV EBNA1 GARs fail to inhibit antigen processing and presentation as determined by using three different in vitro CTL assays. These studies suggest that inhibition of antigen processing and presentation by the EBNA1 GAR may not be an essential mechanism for persistent infection by all LCV and that other mechanisms may be important for immune evasion during LCV infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438828      PMCID: PMC104265     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus.

Authors:  M A Lee; M E Diamond; J L Yates
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Further characterization of a herpesvirus-positive orang-utan cell line and comparative aspects of in vitro transformation with lymphotropic old world primate herpesviruses.

Authors:  H Rabin; R H Neubauer; R F Hopkins; M Nonoyama
Journal:  Int J Cancer       Date:  1978-06-15       Impact factor: 7.396

3.  Hybrid pUC vectors for addition of new restriction enzyme sites to the ends of DNA fragments.

Authors:  R Kay; J McPherson
Journal:  Nucleic Acids Res       Date:  1987-03-25       Impact factor: 16.971

4.  A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes.

Authors:  I A York; C Roop; D W Andrews; S R Riddell; F L Graham; D C Johnson
Journal:  Cell       Date:  1994-05-20       Impact factor: 41.582

5.  Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys.

Authors:  M D Miller; H Yamamoto; A L Hughes; D I Watkins; N L Letvin
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

6.  Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers.

Authors:  Q Y Yao; P Ogan; M Rowe; M Wood; A B Rickinson
Journal:  Int J Cancer       Date:  1989-01-15       Impact factor: 7.396

7.  Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency.

Authors:  J W Gratama; M A Oosterveer; F E Zwaan; J Lepoutre; G Klein; I Ernberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

8.  EBNA-2 of herpesvirus papio diverges significantly from the type A and type B EBNA-2 proteins of Epstein-Barr virus but retains an efficient transactivation domain with a conserved hydrophobic motif.

Authors:  P D Ling; J J Ryon; S D Hayward
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells.

Authors:  M Rowe; D T Rowe; C D Gregory; L S Young; P J Farrell; H Rupani; A B Rickinson
Journal:  EMBO J       Date:  1987-09       Impact factor: 11.598

10.  Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.

Authors:  R J Murray; M G Kurilla; J M Brooks; W A Thomas; M Rowe; E Kieff; A B Rickinson
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

View more
  24 in total

1.  Structural, functional, and genetic comparisons of Epstein-Barr virus nuclear antigen 3A, 3B, and 3C homologues encoded by the rhesus lymphocryptovirus.

Authors:  H Jiang; Y G Cho; F Wang
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  The primary sequence of rhesus monkey rhadinovirus isolate 26-95: sequence similarities to Kaposi's sarcoma-associated herpesvirus and rhesus monkey rhadinovirus isolate 17577.

Authors:  L Alexander; L Denekamp; A Knapp; M R Auerbach; B Damania; R C Desrosiers
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  An Epstein-Barr-related herpesvirus from marmoset lymphomas.

Authors:  Y Cho; J Ramer; P Rivailler; C Quink; R L Garber; D R Beier; F Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

4.  The CD8+ T-cell response to an Epstein-Barr virus-related gammaherpesvirus infecting rhesus macaques provides evidence for immune evasion by the EBNA-1 homologue.

Authors:  Mark H Fogg; Amitinder Kaur; Young-Gyu Cho; Fred Wang
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Comprehensive analysis of Rhesus lymphocryptovirus microRNA expression.

Authors:  Kasandra J-L Riley; Gabrielle S Rabinowitz; Joan A Steitz
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

Review 6.  Simian homologues of Epstein-Barr virus.

Authors:  F Wang; P Rivailler; P Rao; Y Cho
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

7.  Complete nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein-Barr virus animal model.

Authors:  Pierre Rivailler; Hua Jiang; Young-gyu Cho; Carol Quink; Fred Wang
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

8.  Cloning of the rhesus lymphocryptovirus viral capsid antigen and Epstein-Barr virus-encoded small RNA homologues and use in diagnosis of acute and persistent infections.

Authors:  P Rao; H Jiang; F Wang
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

9.  Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques.

Authors:  R Leskowitz; M H Fogg; X Y Zhou; A Kaur; E L V Silveira; F Villinger; P M Lieberman; F Wang; H C Ertl
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

10.  Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation.

Authors:  Sebastien Apcher; Chrysoula Daskalogianni; Benedicte Manoury; Robin Fåhraeus
Journal:  PLoS Pathog       Date:  2010-10-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.